Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer

Journal of Urology

Volumn 158, Issue 3, 1997, Pages 902-907

  Hartley Asp, Beryl ^a   Vukanovic, Jasminka ^b   Joseph, Ingrid B J K ^b   Strandgården, Kerstin ^b   Polacek, Jiri ^b   Isaacs, John T ^b  

^a Pharmacia & Upjohn AB   (Sweden)

^b NONE

Author keywords

Angiogenesis; Castration; Linomide; Prostate tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ROQUINIMEX;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR VOLUME;

EID: 0030742019     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64361-1     Document Type: Article

References (27)

1. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D. and Curley, T.: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol., 147: 931, 1992.
2. Hudes, G. R., Greenberg, R., Krigel R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K. and Comis, R.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Onc., 10: 1754, 1992.
3. Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C. and Flaherty, L. E.: A Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J. Clin. Oncol., 12: 2005, 1994.
4. Hudes, G. H., Obasaju, C., Chapman, A., Gallo, J., McAleer, C. and Greenberg, R.: Phase I study of taxol and estramustine: Preliminary activity in hormone-refractory prostate cancer. Semin. Oncol., 22 (Suppl. 6): 6, 1995.
5. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W. and Folkman, J.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143: 401, 1993.
6. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D. and Bigler, S.: A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, 73: 678, 1994.
7. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, H., Meli, S. and Gasparini, G.: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875, 1992.
8. Wakui, S., Furusato, M., Itoh, T., Sasaki, H., Akiyama, A., Kinoshita, I., Asano, K., Tokuda, T., Aizawa S. and Ushigome, S.: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol., 168: 257, 1992.
9. Vukanovic, J., Pasaniti, A., Hirata, T., Traystman, R. J., Hartley-Asp, B. and Isaacs, J. T.: Antiangiogenic effects of the quinoline-3-carboxamide Linomide. Cancer Res., 53: 1833, 1993.
10. Borgström P., Torres Filho, I. P., Vajkoczy, P., Strandgården, K., Polaçek, J. and Hartley-Asp, B.: The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivo. Cancer Chemother. Pharmacol., 34: 280, 1994.
11. Borgström, P., Torres Filho, I. P. and Hartley-Asp, B.: Inhibition of angiogenesis and metastases of the Lewis Lung carcinoma by the quinoline-3-carboxamide, Linomide®. Anticancer Res., 15: 719, 1995.
12. Vukanovic, J. and Isaacs, J. T.: Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499, 1995.
13. Kalland, T.: Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res., 46: 3018, 1986.
14. Harning, R. and Szalay, J.: A treatment for metastasis of murine ocular melanoma. Investigative Ophtalmology & Visual Science, 29: 1505, 1988.
15. Ichikawa, T., Lamb J. C., Christensson, P. I., Hartley-Asp, B. and Isaacs, J. T.: The antitumor effects of the quinoline-3-carboxamide Linomide on Dunning R-3327 rat prostatic cancers. Cancer Res., 52: 3022, 1992.
16. Vukanovic, J., Hartley-Asp, B. and Isaacs, J. T.: Inhibition of tumor angiogenesis and the therapeutic ability of Linomide against rat prostatic cancers. Prostate, 26: 235, 1995.
17. Isaacs, J. T.: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate, 5: 1, 1984.
18. Gasparini, G. and Harris, A. D.: Does improved control of tumor growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur. J. Cancer, 30A: 201, 1994.
19. Folkman, J.: The role of angiogenesis in tumor growth. Cancer Biol., 3: 65, 1992.
20. Furusato, M., Wakui, S., Sasaki, H., Ito, K. and Ushigome, S.: Tumor angiogenesis in latent prostatic carcinoma. Br. J. Cancer, 70: 1244, 1994.
21. Wakui, S., Furusato, M., Itoh, T., Sasaki, H., Akiyama, A., Kinoshita, I., Asano, K., Tokuda, T., Aizawa, S. and Ushigome, A.: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J. Pathol., 168: 257, 1992.
22. Vukanovic, J. and Isaacs, J. T.: Human prostatic cancer cells sensitive to programmed (apoptotic) death induced by the antiangiogenic agent Linomide. Cancer Res., 55: 3517, 1995.
23. Joseph, I. B. J. K. and Isaacs, J. T.: The antiangiogenic agent, Linomide inhibits TNF-α secretion via inhibition of its synthesis. The Prostate, 29: 183, 1996.
24. Vukanovic, J. and Isaacs, J. T.: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499, 1995.
25. Billström, A., Kinnby K., Lecancder I., Åstedt B.: Production of plasminogen activator inhibitor type-2 in human peripheral blood monocytes upregulated in vitro by the quinoline-3-carboxamide, Linomide. Firbinolysis, 10: 277-283, 1996.
26. Billström A., Linde A., Lecander I., Gjörstrup P., Hedlund G.: Monocyte production of plasminogen activator inhibitor type-2 (PAI-2) increased in healthy volunteers treated with Linomide (roquinimex). In press.
27. Rabbani, S. A., Harakidas, P., Davidson, D. J., Henkin, J. and Mazar, A.: P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer, 63: 840, 1995.